HOPEWELL, N.J., November 22, 2021 — Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that Claudine Prowse, Ph.D., chief financial officer, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29, 2021 to December 2, 2021. A pre-recorded webcast of the presentation will be available beginning at 10:00 AM ET on November 22, 2021, on the company’s website, www.gennao.com, and will be archived for 30 days.
About Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.